https://www.selleckchem.com/pr....oducts/poly-l-lysine
ase significantly COVID-19-related case fatality, indicating a clear priority for viral screening, access to care facilities and vaccination in these populations. We evaluated the effect of prior antiplatelet therapy on large vessel occlusion (LVO) in patients with non-valvular atrial fibrillation (NVAF) newly initiated on apixaban. Patients with acute LVO with acute stroke due to NVAF or stenosis with NVAF started on apixaban within 14days of onset were enrolled. We compared incidence of major bleeding, cerebral hemorrhage, ische
Curtir
Comentario
Compartilhar
